T
Thomas Simmet
Researcher at University of Ulm
Publications - 211
Citations - 15559
Thomas Simmet is an academic researcher from University of Ulm. The author has contributed to research in topics: Proinflammatory cytokine & Monocyte. The author has an hindex of 54, co-authored 202 publications receiving 13691 citations. Previous affiliations of Thomas Simmet include University of Freiburg & French Institute of Health and Medical Research.
Papers
More filters
Journal ArticleDOI
Active targeting of mesoporous silica drug carriers enhances γ-secretase inhibitor efficacy in an in vivo model for breast cancer.
Rainer Wittig,Jessica M. Rosenholm,Eva von Haartman,Jarl Hemming,Felicitas Genze,Lotta Bergman,Thomas Simmet,Mika Lindén,Cecilia Sahlgren +8 more
TL;DR: The results demonstrate that therapeutic efficacy is linked to cellular uptake of MSNPs as opposed to tumor accumulation, and show that MSNP-based delivery of γ-secretase inhibitors is therapeutically effective in both breast and prostate cancer.
Journal ArticleDOI
Substitution of blood coagulation factor X-binding to Ad5 by position-specific PEGylation: Preventing vector clearance and preserving infectivity
Lea Krutzke,Jan M. Prill,Tatiana Engler,Christoph Q. Schmidt,Zhili Xu,Andrew P. Byrnes,Thomas Simmet,Florian Kreppel +7 more
TL;DR: In this paper, a site-specific polyethylene glycol shield was proposed to protect Ad5 vector particles from neutralization by coagulation factor X (FX), which mediates hepatocyte transduction by intravenously-injected Ad5 vectors.
Journal ArticleDOI
Biomedical Potential of mTOR Modulation by Nanoparticles.
TL;DR: Modulation of the mammalian target of rapamycin (mTOR), the principal regulator of cellular homeostasis, underlies the biological effects of engineered nanoparticles, including regulation of cell death/ survival and metabolic responses.
Journal ArticleDOI
Structure and Biomedical Applications of Amyloid Oligomer Nanoparticles
Senthil Kumar,Jessica Meinhardt,Ann-Kathrin Fuchs,Tobias Aumüller,Jörg Leppert,Berthold Büchele,Uwe Knüpfer,Ramadurai Ramachandran,Jay Kant Yadav,Erik Prell,Isabel Morgado,Oliver Ohlenschläger,Uwe Horn,Thomas Simmet,Matthias Görlach,Marcus Fändrich +15 more
TL;DR: It is shown that the amyloid oligomers can be labeled with both fluorescence agents and iron oxide nanoparticles and can target macrophage cells and may provide a new biological nanomaterial for improved targeting, drug release, and medical imaging.
Journal ArticleDOI
Selectivity of C3-opsonin targeted complement inhibitors: A distinct advantage in the protection of erythrocytes from paroxysmal nocturnal hemoglobinuria patients.
Christoph Q. Schmidt,Markus J. Harder,Eva-Maria Nichols,Mario Hebecker,Markus Anliker,Britta Höchsmann,Thomas Simmet,Ádám I. Csincsi,Barbara Uzonyi,Isabel Y. Pappworth,Daniel Ricklin,John D. Lambris,Hubert Schrezenmeier,Mihály Józsi,Kevin J. Marchbank +14 more
TL;DR: It is shown that the approach of FH-CR2 to target C3-opsonins was more efficient in preventing complement activation induced by foreign surfaces, whereas the miniFH variants were substantially more active in controlling complement on PNH erythrocytes.